Experienced healthcare investors know that the Food & Drug Administration (FDA) often looms large. After all, that is the regulatory body that has the final say in whether or not biotechnology and pharmaceutical companies can bring drugs to market. Not surprisingly, the FDA’s approval process was set back by the coronavirus pandemic when, in 2020, [...] The post FDA Rebound Could Help HART Beat Higher appeared first on ETF Trends .